Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
AUPH

AUPH - Aurinia Pharmaceuticals Inc Stock Price, Fair Value and News

$14.570.00 (0.00%)
Market Closed

74/100

AUPH

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

74/100

AUPH

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$18.82

Target 3M

$15.5

Target 6M

$16.54

AUPH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AUPH Price Action

Last 7 days

-1.4%

Last 30 days

-8.3%

Last 90 days

20.2%

Trailing 12 Months

76.8%

AUPH RSI Chart

AUPH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AUPH Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

24.68

Price/Sales (Trailing)

7.23

EV/EBITDA

18.65

Price/Free Cashflow

15.99

AUPH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$18.82

Target 3M

$15.5

Target 6M

$16.54

AUPH Fundamentals

AUPH Revenue

Revenue (TTM)

265.8M

Rev. Growth (Yr)

8.41%

Rev. Growth (Qtr)

4.94%

AUPH Earnings

Earnings (TTM)

77.8M

Earnings Growth (Yr)

119.87%

Earnings Growth (Qtr)

46.66%

AUPH Profitability

Operating Margin

88.93%

EBT Margin

29.96%

Return on Equity

21.28%

Return on Assets

14.76%

Free Cashflow Yield

6.25%

AUPH Investor Care

Buy Backs (1Y)

7.92%

Diluted EPS (TTM)

0.56

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025247.3M260.1M265.8M0
2024191.4M207.1M220.4M235.1M
2023146.8M160.1M158.9M175.5M
202266.3M87.9M129.0M134.0M
202149.0M47.9M46.7M45.6M
2020318.0K318.0K25.2M50.1M
2019426.8K390.5K354.3K318.0K
2018429.3K440.5K451.8K463.0K
2017000418.0K
2016000173.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Aurinia Pharmaceuticals Inc

AUPH
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
 CEO
 WEBSITEauriniapharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES300

Aurinia Pharmaceuticals Inc Frequently Asked Questions

AUPH is the stock ticker symbol of Aurinia Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Aurinia Pharmaceuticals Inc is 1.92 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check AUPH's fair value in chart for subscribers.

The fair value guage provides a quick view whether AUPH is over valued or under valued. Whether Aurinia Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Aurinia Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AUPH.

As of Wed Jan 28 2026, AUPH's PE ratio (Price to Earnings) is 24.68 and Price to Sales (PS) ratio is 7.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AUPH PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Aurinia Pharmaceuticals Inc has provided 0.22 (multiply by 100 for percentage) rate of return.